标题
Angiopoietin-1 and Angiopoietin-2 Inhibitors: Clinical Development
作者
关键词
Tie2 inhibition, Angiopoietin inhibition, Angiogenesis, Anti-angiogenic therapy
出版物
Current Oncology Reports
Volume 21, Issue 3, Pages -
出版商
Springer Nature
发表日期
2019-02-26
DOI
10.1007/s11912-019-0771-9
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Phase I Study of MEDI3617, a Selective Angiopoietin-2 Inhibitor Alone and Combined with Carboplatin/Paclitaxel, Paclitaxel, or Bevacizumab for Advanced Solid Tumors
- (2018) David M. Hyman et al. CLINICAL CANCER RESEARCH
- ENGOT-ov-6/TRINOVA-2: Randomised, double-blind, phase 3 study of pegylated liposomal doxorubicin plus trebananib or placebo in women with recurrent partially platinum-sensitive or resistant ovarian cancer
- (2017) Christian Marth et al. EUROPEAN JOURNAL OF CANCER
- Combined Gene Therapy Using AdsVEGFR2 and AdsTie2 With Chemotherapy Reduces the Growth of Human Ovarian Cancer and Formation of Ascites in Mice
- (2017) Laura Tuppurainen et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- The Selective Tie2 Inhibitor Rebastinib Blocks Recruitment and Function of Tie2 Hi Macrophages in Breast Cancer and Pancreatic Neuroendocrine Tumors
- (2017) Allison S. Harney et al. MOLECULAR CANCER THERAPEUTICS
- Therapeutic targeting of the angiopoietin–TIE pathway
- (2017) Pipsa Saharinen et al. NATURE REVIEWS DRUG DISCOVERY
- Phase II Study of First‐Line Trebananib Plus Sorafenib in Patients with Advanced Hepatocellular Carcinoma
- (2017) Ghassan K. Abou‐Alfa et al. ONCOLOGIST
- Anti-angiogenic agents in ovarian cancer: past, present, and future
- (2016) B. J. Monk et al. ANNALS OF ONCOLOGY
- Systematic analysis of circulating soluble angiogenesis-associated proteins in ICON7 identifies Tie2 as a biomarker of vascular progression on bevacizumab
- (2016) Cong Zhou et al. BRITISH JOURNAL OF CANCER
- Normalization of Tumor Vessels by Tie2 Activation and Ang2 Inhibition Enhances Drug Delivery and Produces a Favorable Tumor Microenvironment
- (2016) Jin-Sung Park et al. CANCER CELL
- Final results of a phase 3 study of trebananib plus weekly paclitaxel in recurrent ovarian cancer (TRINOVA-1): Long-term survival, impact of ascites, and progression-free survival-2
- (2016) Bradley J. Monk et al. GYNECOLOGIC ONCOLOGY
- Phase 1 dose-finding study of rebastinib (DCC-2036) in patients with relapsed chronic myeloid leukemia and acute myeloid leukemia
- (2016) Jorge Cortes et al. HAEMATOLOGICA
- Antiangiogenic therapy in oncology: current status and future directions
- (2016) Gordon C Jayson et al. LANCET
- Novel MET/TIE2/VEGFR2 inhibitor altiratinib inhibits tumor growth and invasiveness in bevacizumab-resistant glioblastoma mouse models
- (2016) Yuji Piao et al. NEURO-ONCOLOGY
- Phase 1 dose-finding study of rebastinib (DCC-2036) in patients with relapsed chronic myeloid leukemia and acute myeloid leukemia
- (2016) Jorge Cortes et al. HAEMATOLOGICA
- VEGF and Intraocular Neovascularization: From Discovery to Therapy
- (2016) Napoleone Ferrara Translational Vision Science & Technology
- Trebananib (AMG 386) plus weekly paclitaxel with or without bevacizumab as first-line therapy for HER2-negative locally recurrent or metastatic breast cancer: A phase 2 randomized study
- (2015) Véronique Diéras et al. BREAST
- Advances in anti-angiogenic agents for ovarian cancer treatment: The role of trebananib (AMG 386)
- (2015) Claudia Marchetti et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- A phase II trial of trebananib (AMG 386; IND#111071), a selective angiopoietin 1/2 neutralizing peptibody, in patients with persistent/recurrent carcinoma of the endometrium: An NRG/Gynecologic Oncology Group trial
- (2015) Kathleen N. Moore et al. GYNECOLOGIC ONCOLOGY
- Trebananib (AMG 386) in Combination With Sunitinib in Patients With Metastatic Renal Cell Cancer: An Open-Label, Multicenter, Phase II Study
- (2015) Michael B. Atkins et al. JOURNAL OF CLINICAL ONCOLOGY
- Real-Time Imaging Reveals Local, Transient Vascular Permeability, and Tumor Cell Intravasation Stimulated by TIE2hi Macrophage-Derived VEGFA
- (2015) A. S. Harney et al. Cancer Discovery
- Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions
- (2014) Naveen S. Vasudev et al. ANGIOGENESIS
- The Combination of Circulating Ang1 and Tie2 Levels Predicts Progression-Free Survival Advantage in Bevacizumab-Treated Patients with Ovarian Cancer
- (2014) A. Backen et al. CLINICAL CANCER RESEARCH
- A phase 1b, open-label study of trebananib in combination with paclitaxel and carboplatin in patients with ovarian cancer receiving interval or primary debulking surgery
- (2014) I. Vergote et al. EUROPEAN JOURNAL OF CANCER
- A phase 1b study of trebananib in combination with pegylated liposomal doxorubicin or topotecan in women with recurrent platinum-resistant or partially platinum-sensitive ovarian cancer
- (2014) Ignace Vergote et al. GYNECOLOGIC ONCOLOGY
- Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial
- (2014) Bradley J Monk et al. LANCET ONCOLOGY
- Role of Angiopoietin-2 in Adaptive Tumor Resistance to VEGF Signaling Blockade
- (2014) Nicolò Rigamonti et al. Cell Reports
- A randomised, double-blind, placebo-controlled phase 2 study of trebananib (AMG 386) in combination with FOLFIRI in patients with previously treated metastatic colorectal carcinoma
- (2013) M Peeters et al. BRITISH JOURNAL OF CANCER
- TIE-2 and VEGFR Kinase Activities Drive Immunosuppressive Function of TIE-2-Expressing Monocytes in Human Breast Tumors
- (2013) M. Ibberson et al. CLINICAL CANCER RESEARCH
- A Phase I, Open-Label Study of Trebananib Combined With Sorafenib or Sunitinib in Patients With Advanced Renal Cell Carcinoma
- (2013) David S. Hong et al. Clinical Genitourinary Cancer
- Phase II randomized, double-blind, placebo-controlled study of AMG 386 (trebananib) in combination with cisplatin and capecitabine in patients with metastatic gastro-oesophageal cancer
- (2012) M. M. Eatock et al. ANNALS OF ONCOLOGY
- Phase 1 study of trebananib (AMG 386), an angiogenesis targeting angiopoietin-1/2 antagonist, in Japanese patients with advanced solid tumors
- (2012) Toshihiko Doi et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Angiopoietin-2 Functions as a Tie2 Agonist in Tumor Models, Where It Limits the Effects of VEGF Inhibition
- (2012) C. Daly et al. CANCER RESEARCH
- Inhibition of endothelial/smooth muscle cell contact loss by the investigational angiopoietin-2 antibody MEDI3617
- (2012) Nikolett Molnar et al. MICROVASCULAR RESEARCH
- Multiple Effects of Angiopoietin-2 Blockade on Tumors
- (2011) Claire E. Lewis et al. CANCER CELL
- Targeting the ANG2/TIE2 Axis Inhibits Tumor Growth and Metastasis by Impairing Angiogenesis and Disabling Rebounds of Proangiogenic Myeloid Cells
- (2011) Roberta Mazzieri et al. CANCER CELL
- Randomized, Double-Blind, Placebo-Controlled Phase II Study of AMG 386 Combined With Weekly Paclitaxel in Patients With Recurrent Ovarian Cancer
- (2011) Beth Y. Karlan et al. JOURNAL OF CLINICAL ONCOLOGY
- Control of vascular morphogenesis and homeostasis through the angiopoietin–Tie system
- (2009) Hellmut G. Augustin et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started